Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report
Abstract Mesenchymal–epithelial transition (MET) exon 14 (METex14) skipping mutation is a rare (3%–4%) driver mutation in non‐small cell lung cancer (NSCLC). Tepotinib, a selective MET inhibitor, has shown promise in treating METex14 skipping‐mutated NSCLC. However, its feasibility for perioperative...
Збережено в:
| Автори: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2024-11-01
|
| Серія: | Thoracic Cancer |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1111/1759-7714.15459 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|